OBJECTIVE： To evaluate the effectiveness of Corbrin capsules for respiratory systemdisease  systematically，in order to provide evidence-based reference for clinical use. METHODS： Retrieved from CJFD，China Dissertation Database，Wanfang database，VIP，Cochrane Library，Medline and PubMed，randomized controlled trials （RCTs） about conventional treatment plan （trial group） vs. single treatment plan （control group） in the treatment of respiratory system disease. The quality of included studies were evaluated after extracting data and modifying according to Jadad scale and Cochrane bias risk assessment scale. Meta-analysis was performed by using RevMan 5.2 statistical software. RESULTS： A total of 17 RCTs were included，involving 1 801 patients. The results of Meta-analysis showed that response rate [RD＝0.15，95％CI（0.10，0.19），P＜0.001]，FEV1[MD＝0.21，95％CI（0.14，0.28），P＜0.001]，FVC [MD＝0.26，95％CI（0.05，0.47），P＜0.001] and FEV1/FEV [MD＝5.60，95％CI（3.42，7.78），P＜0.001] of trial group were significantly higher than those of control group，with statistical significance.   CONCLUSIONS： Corbrin capsules have good therapeutic efficacy for respiratory system disease and effectively improve lung related indicators.